Your browser is no longer supported. Please, upgrade your browser.
Settings
SEEL [NASD]
Seelos Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.57 Insider Own4.85% Shs Outstand102.23M Perf Week-10.47%
Market Cap247.35M Forward P/E- EPS next Y-0.55 Insider Trans0.00% Shs Float74.77M Perf Month-16.30%
Income-33.40M PEG- EPS next Q-0.12 Inst Own26.80% Short Float6.58% Perf Quarter-62.86%
Sales- P/S- EPS this Y83.10% Inst Trans0.83% Short Ratio1.09 Perf Half Y-13.16%
Book/sh0.36 P/B6.42 EPS next Y14.70% ROA-174.60% Target Price- Perf Year128.71%
Cash/sh0.36 P/C6.39 EPS next 5Y- ROE-353.90% 52W Range0.56 - 6.60 Perf YTD46.20%
Dividend- P/FCF- EPS past 5Y67.30% ROI- 52W High-65.00% Beta3.06
Dividend %- Quick Ratio3.10 Sales past 5Y- Gross Margin- 52W Low312.28% ATR0.20
Employees9 Current Ratio3.10 Sales Q/Q- Oper. Margin- RSI (14)36.38 Volatility6.96% 8.07%
OptionableYes Debt/Eq0.22 EPS Q/Q-95.40% Profit Margin- Rel Volume0.36 Prev Close2.33
ShortableYes LT Debt/Eq0.13 Earnings- Payout- Avg Volume4.50M Price2.31
Recom2.00 SMA20-11.63% SMA50-23.94% SMA200-17.19% Volume1,660,504 Change-0.86%
Jul-01-21Initiated Guggenheim Buy $8
Jun-01-21Initiated Cantor Fitzgerald Overweight $10
May-17-21Downgrade ROTH Capital Buy → Neutral
Mar-30-21Initiated B. Riley Securities Buy $15
Nov-14-19Initiated The Benchmark Company Speculative Buy $4
May-14-19Initiated ROTH Capital Buy
Jul-14-21 12:57PM  
08:00AM  
Jul-07-21 11:12AM  
07:00AM  
Jul-06-21 04:47PM  
08:00AM  
Jun-29-21 02:42PM  
Jun-28-21 07:00AM  
Jun-01-21 01:22PM  
08:00AM  
May-27-21 07:00AM  
May-24-21 04:05PM  
08:33AM  
May-21-21 08:00AM  
May-20-21 08:19AM  
May-19-21 04:01PM  
08:54AM  
May-17-21 06:52PM  
09:17AM  
06:00AM  
May-10-21 08:00AM  
Apr-20-21 07:00AM  
Apr-19-21 08:00AM  
Apr-15-21 09:00AM  
Apr-09-21 08:34AM  
Apr-06-21 07:00AM  
Mar-12-21 12:32PM  
11:44AM  
Mar-05-21 09:00AM  
Feb-18-21 08:38AM  
08:14AM  
07:00AM  
Feb-17-21 08:00AM  
Feb-01-21 08:00AM  
Jan-29-21 08:00AM  
Jan-28-21 10:07AM  
Jan-27-21 08:59AM  
08:00AM  
Jan-26-21 08:30AM  
Jan-25-21 04:01PM  
Jan-22-21 09:00AM  
Jan-15-21 08:30AM  
Jan-06-21 08:45AM  
Jan-05-21 09:00AM  
Dec-21-20 09:00AM  
Dec-15-20 09:00AM  
Dec-14-20 09:00AM  
Dec-11-20 10:00AM  
Dec-08-20 09:00AM  
Dec-02-20 09:00AM  
Nov-29-20 11:41AM  
Nov-19-20 08:45AM  
Nov-09-20 09:24AM  
Oct-26-20 09:00AM  
Oct-22-20 09:00AM  
Sep-28-20 03:30PM  
Sep-23-20 09:00AM  
Sep-14-20 09:00AM  
Sep-10-20 09:00AM  
Sep-09-20 02:00PM  
Sep-04-20 09:08AM  
Aug-28-20 08:00AM  
Aug-25-20 11:00AM  
Aug-10-20 09:15AM  
Jul-21-20 09:00AM  
Jul-16-20 04:31PM  
04:30PM  
Jun-25-20 08:00AM  
Jun-23-20 07:00AM  
Jun-17-20 09:08AM  
Jun-15-20 08:01AM  
Jun-04-20 07:26PM  
May-28-20 07:01AM  
May-19-20 11:42AM  
09:01AM  
May-18-20 08:01AM  
May-15-20 10:30AM  
07:30AM  
May-12-20 08:05AM  
May-04-20 08:01AM  
Apr-30-20 01:31PM  
Apr-08-20 09:01AM  
Mar-24-20 08:01AM  
Mar-16-20 04:30PM  
Mar-11-20 08:30PM  
04:15PM  
08:01AM  
Mar-06-20 08:01AM  
Feb-26-20 08:01AM  
Feb-19-20 08:02AM  
Feb-17-20 08:57AM  
Feb-13-20 04:30PM  
Feb-10-20 08:00PM  
Jan-28-20 01:58PM  
08:02AM  
Jan-22-20 07:30AM  
Jan-10-20 08:30AM  
07:31AM  
Jan-06-20 08:02AM  
Dec-16-19 07:00AM  
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.